620 related articles for article (PubMed ID: 15368525)
1. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A
J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
[TBL] [Abstract][Full Text] [Related]
3. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope.
Brinster C; Muguet S; Lone YC; Boucreux D; Renard N; Fournillier A; Lemonnier F; Inchauspé G
Hepatology; 2001 Dec; 34(6):1206-17. PubMed ID: 11732011
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus mutation affects proteasomal epitope processing.
Seifert U; Liermann H; Racanelli V; Halenius A; Wiese M; Wedemeyer H; Ruppert T; Rispeter K; Henklein P; Sijts A; Hengel H; Kloetzel PM; Rehermann B
J Clin Invest; 2004 Jul; 114(2):250-9. PubMed ID: 15254592
[TBL] [Abstract][Full Text] [Related]
5. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.
Fytili P; Dalekos GN; Schlaphoff V; Suneetha PV; Sarrazin C; Zauner W; Zachou K; Berg T; Manns MP; Klade CS; Cornberg M; Wedemeyer H
Vaccine; 2008 Jul; 26(31):3818-26. PubMed ID: 18582999
[TBL] [Abstract][Full Text] [Related]
6. Relation between viral fitness and immune escape within the hepatitis C virus protease.
Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
Gut; 2006 Feb; 55(2):266-74. PubMed ID: 16105887
[TBL] [Abstract][Full Text] [Related]
7. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
Martin P; Parroche P; Pajot A; Chatel L; Barreto C; Touat L; Dubois V; Rohrlich PS; Bain C; Trépo C; Negro F; Inchauspé G; Fournillier A
Microbes Infect; 2006 Aug; 8(9-10):2432-41. PubMed ID: 16859951
[TBL] [Abstract][Full Text] [Related]
8. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
9. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens.
Urbani S; Uggeri J; Matsuura Y; Miyamura T; Penna A; Boni C; Ferrari C
Hepatology; 2001 Jun; 33(6):1533-43. PubMed ID: 11391544
[TBL] [Abstract][Full Text] [Related]
10. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
11. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
Engler OB; Schwendener RA; Dai WJ; Wölk B; Pichler W; Moradpour D; Brunner T; Cerny A
Vaccine; 2004 Nov; 23(1):58-68. PubMed ID: 15519708
[TBL] [Abstract][Full Text] [Related]
12. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins.
Gerlach JT; Ulsenheimer A; Grüner NH; Jung MC; Schraut W; Schirren CA; Heeg M; Scholz S; Witter K; Zahn R; Vogler A; Zachoval R; Pape GR; Diepolder HM
J Virol; 2005 Oct; 79(19):12425-33. PubMed ID: 16160170
[TBL] [Abstract][Full Text] [Related]
13. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection.
Wertheimer AM; Miner C; Lewinsohn DM; Sasaki AW; Kaufman E; Rosen HR
Hepatology; 2003 Mar; 37(3):577-89. PubMed ID: 12601356
[TBL] [Abstract][Full Text] [Related]
14. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
15. The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection.
López-Labrador FX; He XS; Berenguer M; Cheung RC; Wright TL; Greenberg HB
J Immunol Methods; 2004 Apr; 287(1-2):91-9. PubMed ID: 15099758
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients.
Godkin A; Jeanguet N; Thursz M; Openshaw P; Thomas H
Eur J Immunol; 2001 May; 31(5):1438-46. PubMed ID: 11465100
[TBL] [Abstract][Full Text] [Related]
17. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.
Wedemeyer H; Mizukoshi E; Davis AR; Bennink JR; Rehermann B
J Virol; 2001 Dec; 75(23):11392-400. PubMed ID: 11689620
[TBL] [Abstract][Full Text] [Related]
19. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul JM; Barry R; Inchauspé G
Vaccine; 2007 Oct; 25(42):7339-53. PubMed ID: 17875349
[TBL] [Abstract][Full Text] [Related]
20. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
